Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) has initiated the randomized portion of its SELECT-AML-1 trial, with initial results expected in Q4 2023. The company received FDA Fast Track designation for tamibarotene in treating higher-risk myelodysplastic syndrome (HR-MDS). Enrollment for the SELECT-MDS-1 trial is on track for completion in Q4 2023, with pivotal data anticipated in Q3 2024. Financially, Syros reported a net loss of $4.8 million for Q4 2022, compared to a loss of $23.8 million in Q4 2021. The company maintains a robust cash position of $202.3 million, expected to fund operations through mid-2025.
Syros Pharmaceuticals (NASDAQ:SYRS) announces CEO Nancy Simonian, M.D., will participate in two investor conferences in March. The first is the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 a.m. ET in Boston, focusing on Novel Oncology Targets. The second event is the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET, conducted virtually. Syros is advancing treatments for hematologic malignancies through its clinical programs, including tamibarotene and SY-2101. For more details, visit www.syros.com.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. The call can be accessed by dialing (888) 575-5167 for domestic callers or (416) 764-8687 for international callers, using conference ID 74534085. Syros focuses on advancing treatment standards for hematologic malignancies. Its clinical pipeline includes tamibarotene for higher-risk myelodysplastic syndrome and acute myeloid leukemia, and SY-2101, an oral arsenic trioxide formulation for acute promyelocytic leukemia. More details are available on their website.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
